Abses Hepar Amoeba

01Pathophysiology

Amoebic liver abscess is the most common extraintestinal manifestation of infection with Entamoeba histolytica. The organism is transmitted through the fecal-oral route, typically via ingestion of cysts in contaminated water or food. Once ingested, cysts pass through the stomach and excyst in the small intestine, releasing trophozoites that colonize the cecum and ascending colon.

The trophozoites produce cysteine proteases and amoebapores that destroy the colonic epithelium, allowing tissue invasion. From the intestinal wall, the organisms enter the portal venous circulation and travel to the liver. This explains why the right hepatic lobe is disproportionately affected: the right lobe receives the majority of portal venous drainage from the cecum and ascending colon via the superior mesenteric vein.

Once in the liver, trophozoites cause liquefactive necrosis of hepatocytes and surrounding tissue. The host inflammatory response recruits neutrophils, but the amoebae destroy these inflammatory cells through contact-dependent lysis. The resulting abscess cavity contains a characteristic acellular, proteinaceous debris that appears as reddish-brown ("anchovy paste" or "chocolate sauce") material on aspiration. Notably, this material is composed of necrotic hepatocytes, dead inflammatory cells, and blood rather than true pus with live bacteria, which is why Gram stain and culture of the aspirate are typically negative for bacteria.

The reason patients present with right upper quadrant pain and fever is directly linked to this expanding necrotic lesion stretching the hepatic capsule. If the abscess sits near the dome of the liver, diaphragmatic irritation produces referred pain to the right shoulder and can cause sympathetic right-sided pleural effusion, explaining the basilar lung findings on exam. The subacute timeline (days to weeks) reflects the progressive nature of the tissue necrosis.

An important clinical nuance is that fewer than one-third of patients with amoebic liver abscess have concurrent dysentery. The intestinal infection may have resolved weeks to months before the abscess becomes symptomatic, so the absence of diarrhea should never lead you away from this diagnosis.

02Classification and Clinical Manifestation

03Diagnostic Workup

Approach to the workup: When you encounter a patient with right upper quadrant pain, fever, and a travel history to an endemic region, the first step is an abdominal ultrasound. Ultrasound is rapid, noninvasive, and highly sensitive for detecting liver lesions. It will typically show a solitary, round, hypoechoic lesion in the right lobe without the internal septations or debris levels that might suggest a pyogenic abscess.

Once imaging suggests a liver abscess, the next step is to distinguish amoebic from pyogenic etiology. This is where amoebic serology becomes the confirmatory test. The IgG ELISA has sensitivity exceeding 95% in patients with hepatic involvement and is the single most useful test to confirm the diagnosis. However, be aware that serology can remain positive for years after a treated infection, so in patients from endemic areas with a history of prior amebiasis, a positive result must be interpreted alongside clinical context.

Blood cultures should be drawn to rule out a pyogenic abscess. In amoebic liver abscess, blood cultures are characteristically negative. If blood cultures grow gram-negative rods or anaerobes, the diagnosis shifts toward pyogenic abscess, which changes the management entirely.

Routine aspiration of an amoebic liver abscess is not required if the clinical and serological picture is clear and the patient responds to metronidazole. Aspiration is reserved for: (1) diagnostic uncertainty, particularly when pyogenic abscess cannot be excluded, (2) large abscesses (greater than 10 cm or in the left lobe, due to rupture risk), (3) failure to respond to 3 to 5 days of medical therapy, and (4) imminent rupture. The classic "anchovy paste" aspirate is highly suggestive but not always present, and trophozoites are rarely found in the aspirate because they reside at the abscess wall margin, not in the necrotic center.

Stool studies are low-yield in this setting. More than 60% of patients with amoebic liver abscess have no detectable organisms in their stool at the time of presentation, because the intestinal phase may have already resolved.

04Management and Treatment

The cornerstone of treatment is metronidazole, which is a nitroimidazole that penetrates well into the abscess cavity and is highly effective against trophozoites. The standard dose is 750 mg orally three times daily for 7 to 10 days. Most patients show clinical improvement (defervescence, pain reduction) within 48 to 72 hours of starting therapy. If the patient cannot tolerate oral medications, intravenous metronidazole at 500 mg every 8 hours can be substituted.

Tinidazole is an acceptable alternative, offering the advantage of a shorter treatment course (3 to 5 days) and better gastrointestinal tolerability. On an exam, if a patient develops intolerable nausea or a disulfiram-like reaction from metronidazole, tinidazole is the appropriate next step.

After completing the tissue amoebicide, you must follow with a luminal agent. This is a frequently tested concept. Metronidazole achieves excellent tissue levels but does not reliably clear cysts from the intestinal lumen. Failing to add a luminal agent leads to persistent intestinal carriage, risk of relapse, and ongoing fecal transmission. Paromomycin is the preferred luminal agent, dosed at 25 to 35 mg/kg/day divided into three doses for 7 days. This is a non-absorbable aminoglycoside that acts locally in the gut lumen.

Percutaneous aspiration or drainage is not routine. Indications for drainage include:

• Abscess greater than 10 cm in diameter (high rupture risk)

• Left lobe abscess (risk of pericardial rupture)

• Clinical failure after 3 to 5 days of metronidazole

• Concern for superinfection or pyogenic abscess that cannot be excluded

• Signs of impending rupture (thinning of the capsule on imaging)

Surgical intervention is reserved for rupture into the peritoneum or pericardium and for abscesses that fail percutaneous drainage.

Contraindications and special considerations: Metronidazole should be used with caution in the first trimester of pregnancy, though in life-threatening hepatic amebiasis the benefit generally outweighs the risk. Patients must be counseled to avoid alcohol during and for at least 48 hours after metronidazole therapy due to the disulfiram-like reaction. In patients with severe hepatic dysfunction, dose adjustment is generally not required for standard courses, but prolonged therapy should be monitored.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students miss this diagnosis is by requiring diarrhea to be present before considering amoebic liver abscess. The majority of patients with hepatic involvement do not have active intestinal symptoms at the time of presentation, because the colonic phase may have occurred weeks to months prior. A vignette describing a young man with travel history, right upper quadrant pain, and fever but no diarrhea is still pointing you toward this diagnosis.

The second major trap involves the two-drug treatment principle. Students frequently select metronidazole alone as the complete answer. The exam tests whether you understand that a tissue amoebicide must be followed by a luminal agent. Any answer that omits paromomycin (or an equivalent luminal drug) is incomplete and represents a failure to prevent relapse and ongoing transmission.

Another tested concept is the distinction between amoebic and pyogenic liver abscess. The vignette will use clues like age, travel history, a single right lobe lesion, negative blood cultures, and positive amoebic serology to steer you toward amoebic etiology. In contrast, an older patient with diabetes or recent biliary instrumentation, multiple lesions, and positive blood cultures should point you toward pyogenic abscess, which requires antibiotics and typically percutaneous drainage.

Finally, be alert for the left lobe abscess complication question. If the stem describes a patient with an amoebic abscess in the left hepatic lobe who develops sudden hypotension, muffled heart sounds, and jugular venous distension, the answer is pericardial rupture with tamponade, which requires emergent pericardiocentesis. This is a low-frequency but high-yield scenario that tests your ability to recognize a life-threatening complication based on abscess location.

The core competency being tested across all these questions is your ability to integrate epidemiologic risk factors, imaging characteristics, and serologic data to distinguish amoebic from pyogenic abscess, and to recall the complete two-phase treatment regimen without omitting the luminal agent.